(Q39520488)

English

Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial

scientific article published on 28 October 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 September 2017

Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial (English)

1 reference

Europe PubMed Central

12 September 2017

multicenter clinical trial

0 references

0 references

object named as

Maia Lesosky

6

0 references

object named as

Madhukar Pai

9

0 references

13

object named as

Peter Mwaba

1 reference

Europe PubMed Central

12 September 2017

Michael Hoelscher

10

object named as

Michael Hoelscher

1 reference

Europe PubMed Central

12 September 2017

16

object named as

Keertan Dheda

1 reference

Europe PubMed Central

12 September 2017

2

object named as

Lynn Zijenah

1 reference

Europe PubMed Central

12 September 2017

4

object named as

Petra Clowes

1 reference

Europe PubMed Central

12 September 2017

author name string

Grant Theron

1

1 reference

Europe PubMed Central

12 September 2017

Duncan Chanda

3

1 reference

Europe PubMed Central

12 September 2017

Andrea Rachow

5

1 reference

Europe PubMed Central

12 September 2017

Wilbert Bara

7

1 reference

Europe PubMed Central

12 September 2017

Stanley Mungofa

8

1 reference

Europe PubMed Central

12 September 2017

David Dowdy

11

1 reference

Europe PubMed Central

12 September 2017

Alex Pym

12

1 reference

Europe PubMed Central

12 September 2017

Peter Mason

14

1 reference

Europe PubMed Central

12 September 2017

Jonny Peter

15

1 reference

Europe PubMed Central

12 September 2017

TB-NEAT team

17

1 reference

Europe PubMed Central

12 September 2017

language of work or name

0 references

publication date

28 October 2013

1 reference

Europe PubMed Central

12 September 2017

1 reference

Europe PubMed Central

12 September 2017

383

1 reference

Europe PubMed Central

12 September 2017

424-435

1 reference

Europe PubMed Central

12 September 2017

9915

1 reference

Europe PubMed Central

12 September 2017

Scaling up interventions to achieve global tuberculosis control: progress and new developments

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Drivers of inequality in Millennium Development Goal progress: a statistical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of new tuberculosis diagnostics on transmission: why context matters

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of Xpert MTB/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Improving the reporting of pragmatic trials: an extension of the CONSORT statement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid molecular detection of tuberculosis and rifampin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

TBscore: Signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The Bandim tuberculosis score: reliability and comparison with the Karnofsky performance score.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact and cost of scaling up GeneXpert MTB/RIF in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Location of Xpert® MTB/RIF in centralised laboratories in South Africa undermines potential impact

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Test research versus diagnostic research

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of two methods for acquisition of sputum samples for diagnosis of suspected tuberculosis in smear-negative or sputum-scarce people: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962073-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(13)62073-5

1 reference

Europe PubMed Central

12 September 2017

1 reference

Europe PubMed Central

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39520488&oldid=1835040914"